Our group of scientists and clinicians has been continuously funded by the California Institute of Regenerative Medicine (CIRM) to develop a first-in class pluripotent stem cell-based therapy for focal articular cartilage lesions. This translational grant provided funds to develop Plurocart, an off-the-shelf allogeneic cryopreserved biological implant composed of highly purified human stem cell-derived immature articular chondrocytes. This technology is now ready for GMP manufacturing and clinical application. All goals of the grant have been achieved as proposed.